Kirk Campbell, MD
- ASSOCIATE PROFESSOR | Medicine, Nephrology
Kirk Campbell, MD, is an Associate Professor in the Division of Nephrology and the Vice Chair of Diversity and Inclusion. He is also the Director of the Nephrology Fellowship Program and an
Ombudsperson for medical students at the Icahn School of Medicine at
Mount Sinai. He is board certified in Nephrology.
Dr. Campbell is a graduate of the University of Connecticut School of Medicine and completed his residency training in Internal Medicine at Yale-New Haven Hospital and a clinical and research fellowship in Nephrology at The Mount Sinai Hospital. In addition to treating patients with renal disease, Dr. Campbell leads an NIH-funded research program focused on understanding the mechanism of podocyte injury in the progression of proteinuric kidney diseases.
He is a Nephcure Foundation Young Investigator Awardee and a recipient of the Carl Gottschalk Research Scholar Grant from the American Society of Nephrology. Dr. Campbell is a member of the Medical Advisory Board of the National Kidney Foundation Serving Greater New York.
Multi-Disciplinary Training AreaPharmacology and Therapeutics Discovery [PTD]
MD, University of Connecticut
Residency, Internal Medicine, Yale-New Haven Hospital
Fellowship, Nephrology, Mount Sinai Hospital
Kidney podocytes are the target cells for injury in human glomerular disease, a significant cause of end stage kidney failure. Primary and secondary pathogenic processes affecting podocytes account for 90% of end-stage kidney disease at a cost of 20 billion dollars per year in the US. A reduction in podocyte number (podocytopenia) directly correlates with the progression of several proteinuric kidney diseases including focal segmental glomerulosclerosis (FSGS), IgA nephropathy and diabetic nephropathy. Despite significant advances in the characterization of the molecular architecture of podocytes, the mechanisms underlying their survival, injury and loss remain poorly understood. Validated therapeutic targets are scarce and there are currently no podocyte-specific drugs commercially available. The overall goal of our research program is to enhance the pipeline of putative therapeutic targets available to tackle human glomerular disease by elucidating the details and functional significance of key signaling pathways that regulate podocyte injury and survival. We utilize cell-based assays and rodent models to identify and characterize key mediators of glomerular disease progression. Please go to The Campbell Laboratory.